140 likes | 162 Views
The increasing prevalence of immune system dysfunction, characterized by the antibodies attacking the proteins responsible for maintaining skin cell cohesion, is driving the market growth.
E N D
ABOUT IMARC International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Description and Highlights Pemphigus Vulgaris Market 2023-2033 The newly published report by IMARC Group, titled “Pemphigus Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033“, presents a comprehensive analysis of the pemphigus vulgaris market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the seven major markets (7MM). The report also highlights key segments and market drivers, as well as challenges faced by industry players. Industry Definition and Application: Pemphigus vulgaris is an uncommon autoimmune disorder caused by painful blistering and erosions that affect the skin and mucous membranes. It occurs in various body parts, including the mouth, throat, nose, genitals, abdomen, and more. Its symptoms include the development of delicate, fluid-filled blisters that result in painful, vulnerable open sores prone to infection. Other indications include itching, burning, pain in affected areas, fever, fatigue, and weight loss. Pemphigus vulgaris is diagnosed by a combination of clinical examination, skin biopsy, and diagnostic procedures to assess the extent and severity of blistering and erosion and identify characteristic changes in cells and tissues. In addition to this, blood tests are also ordered to detect the presence of specific antibodies associated with pemphigus vulgaris.
Report Description and Highlights What are the growth prospects and trends in the industry? The increasing prevalence of immune system dysfunction, characterized by the antibodies attacking the proteins responsible for maintaining skin cell cohesion, is driving the market growth. Additionally, the growing utilization of various medications, including nonsteroidal anti-inflammatory drugs, penicillamine, and angiotensin-converting enzyme inhibitors, which can trigger the onset of the condition, is contributing to the market growth. Furthermore, the rising adoption of immunosuppressive agents in combination with corticosteroids to regulate the immune system and prevent the formation of new blisters is catalyzing the market growth. Moreover, the introduction of plasmapheresis as a treatment option for severe cases that are unresponsive to other therapies is acting as another growth-inducing factor. Moreover, the increasing adoption of indirect immunofluorescence, which utilizes fluorescent antibodies to detect the presence of autoantibodies, for diagnosing the disorder is fueling the market growth. Apart from this, the growing demand for intravenous immunoglobulin therapy among patients who cannot tolerate systemic corticosteroids is supporting the market growth. Request a Sample Report: https://www.imarcgroup.com/pemphigus-vulgaris-market/requestsample
Report Description and Highlights What is included in the report segmentation? The report covers the following aspects: Report Period: • Base Year: 2022 • Historical Period: 2017-2022 • Market Forecast: 2023-2033 Countries Included: • United States • Germany • France
Report Description and Highlights • United Kingdom • Italy • Spain • Japan Analysis Covered Across Each Country • Historical, current, and future epidemiology scenario • Historical, current, and future performance of the Pemphigus Vulgaris market • Historical, current, and future performance of various therapeutic categories in the market • Sales of various drugs across the Pemphigus Vulgaris market • Reimbursement scenario in the market • In-market and pipeline drugs
Report Description and Highlights In-Market Drugs • Drug Overview • Mechanism of Action • Regulatory Status • Clinical Trial Results • Drug Uptake and Market Performance Late-Stage Pipeline Drugs • Drug Overview • Mechanism of Action • Regulatory Status • Clinical Trial Results • Regulatory Status View Report TOC, Figures and Tables: https://www.imarcgroup.com/pemphigus-vulgaris-market
Key Questions Answered in the Report • How has the Pemphigus Vulgaris Market performed so far and how will it perform in the coming years? • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033? • What was the country-wise size of the Pemphigus Vulgaris Market across the seven major markets in 2022 and what will it look like in 2033? • What is the growth rate of the Pemphigus Vulgaris Marketacross the seven major markets and what will be the expected growth over the next ten years? • What are the key unmet needs in the market?
Table of Contents 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary
Table of Contents 4 Pemphigus Vulgaris - Introduction 4.1 Overview 4.2 Regulatory Process 4.3 Epidemiology (2017-2022) and Forecast (2023-2033) 4.4 Market Overview (2017-2022) and Forecast (2023-2033) 4.5 Competitive Intelligence 5 Pemphigus Vulgaris - Disease Overview 5.1 Introduction 5.2 Symptoms and Diagnosis 5.3 Pathophysiology 5.4 Causes and Risk Factors 5.5 Treatment Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/pemphigus-vulgaris-market/toc
Disclaimer © 2023 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.